Table 1.
Basic characteristics of GRA-positive and GRA-negative PA patients.
| Variables | GRA-Positive (N = 79) |
GRA-Negative (N = 114) |
p Value |
|---|---|---|---|
| Women/men (%) | 39/40 (49.4%/50.6%) | 65/49 (57.0%/43.0%) | 0.298 |
| Age (years) | 51.2 ± 13.8 | 48.1 ± 13.0 | 0.081 |
| Body weight (kg) | 72.5 ± 17.0 | 71.0 ± 13.7 | 0.442 |
| BMI (kg/m2) | 26.5 ± 4.4 | 26.1 ± 4.2 | 0.448 |
| eGFR (MDRD) (ml/min/1.73 m2) | 92.6 ± 36.7 | 88.7 ± 29.8 | 0.338 |
| Na (mmol/L) | 140.5 ± 2.9 | 140.0 ± 3.6 | 0.450 |
| K (mmol/L) | 3.82 ± 0.64 | 3.79 ± 0.62 | 0.399 |
| Cholesterol (mg/dL) | 180.4 ± 38.8 | 183.9 ± 34.5 | 0.562 |
| Triglyceride (mg/dL) | 136.7 ± 76.9 | 133.9 ± 81.1 | 0.820 |
| LDL-C (mg/dL) | 111.6 ± 29.7 | 108.7 ± 27.4 | 0.542 |
| TTKG | 5.43 ± 2.1 | 5.49 ± 2.7 | 0.880 |
| pH | 7.41 ± 0.04 | 7.40 ± 0.03 | 0.226 |
| HCO3 | 26.3 ± 3.1 | 25.8 ± 3.6 | 0.601 |
| Cortisol (μg/dL) | 11.8 ± 6.0 | 11.4 ± 4.7 | 0.740 |
| SBP (mmHg) | 156 ± 20 | 152 ± 22 | 0.215 |
| DBP (mmHg) | 94 ± 15 | 92 ± 15 | 0.591 |
| Intact PTH (pg/mL) | 67.01 ± 34.23 | 61.48 ± 31.54 | 0.122 |
| Cystatin C (mg/L) | 0.75 ± 0.13 | 0.85 ± 0.31 | 0.112 |
| CRP (mg/dL) | 0.27 ± 0.47 | 0.42 ± 0.92 | 0.329 |
| PAC (ng/dL) | 41.8 ± 30.9 | 55.1 ± 37.6 | 0.008 ** |
| PRA (ng/mL per hour) | 0.86 ± 1.46 | 0.80 ± 1.32 | 0.469 |
| ARR (ng/dL per ng/mL-h) | 364.6 ± 720.4 | 872.0 ± 1968.0 | 0.013 * |
| Urine Aldo | 19.1 ± 14.7 | 15.8 ± 18.4 | 0.271 |
| ACR (μg/mg) | 0.13 ± 0.43 | 0.19 ± 0.92 | 0.622 |
| Diabetes | 15 (19.0%) | 18 (15.8%) | 0.552 |
| MACE | 12 (15.2%) | 8 (7.0%) | 0.119 |
| Number of Anti-HTN drugs | 3 (0–8) | 3 (0–8) | 0.900 |
| Family member of HTN | 2 (1–3) | 1 (1–3) | 0.831 |
Abbreviations: ACR, urine albumin/creatinine ratio; ARR, aldosterone renin ratio; CRP, C-reactive protein; DBP, diastolic blood pressure; eGFR (MDRD), estimated glomerular filtration rate (Modification of Diet in Renal Disease formula); family member of HTN, family history of hypertension; intact PTH, intact parathyroid hormone; K, potassium; MACE, major adverse cardiovascular event; number of anti-HTN drugs, number of antihypertensives drugs in use; Na, sodium; PAC, plasma aldosterone; PRA, plasma renin activity; urine aldo, urine aldosterone; SBP, systolic blood pressure; TTKG, transtubular potassium gradient. * p < 0.05, ** p < 0.01.